TY - JOUR
T1 - Personalized medicine for allergy treatment
T2 - Allergen immunotherapy still a unique and unmatched model
AU - Incorvaia, Cristoforo
AU - Al-Ahmad, Mona
AU - Ansotegui, Ignacio J.
AU - Arasi, Stefania
AU - Bachert, Claus
AU - Bos, Catherine
AU - Bousquet, Jean
AU - Bozek, Andrzéj
AU - Caimmi, Davide
AU - Calderón, Moises A.
AU - Casale, Thomas
AU - Custovic, Adnan
AU - De Blay, Frédéric
AU - Demoly, Pascal
AU - Devillier, Philippe
AU - Didier, Alain
AU - Fiocchi, Alessandro
AU - Fox, Adam T.
AU - Gevaert, Philippe
AU - Gomez, Maximiliano
AU - Heffler, Enrico
AU - Ilina, Natalia
AU - Irani, Carla
AU - Jutel, Marek
AU - Karagiannis, Efstrathios
AU - Klimek, Ludger
AU - Kuna, Piotr
AU - O'Hehir, Robin
AU - Kurbacheva, Oxana
AU - Matricardi, Paolo M.
AU - Morais-Almeida, Mario
AU - Mosges, Ralph
AU - Novak, Natalija
AU - Okamoto, Yoshitaka
AU - Panzner, Petr
AU - Papadopoulos, Nikolaos G.
AU - Park, Hae Sim
AU - Passalacqua, Giovanni
AU - Pawankar, Ruby
AU - Pfaar, Oliver
AU - Schmid-Grendelmeier, Peter
AU - Scurati, Silvia
AU - Tortajada-Girbés, Miguel
AU - Vidal, Carmen
AU - Virchow, J. Christian
AU - Wahn, Ulrich
AU - Worm, Margitta
AU - Zieglmayer, Petra
AU - Canonica, Giorgio W.
PY - 2021/4
Y1 - 2021/4
N2 - The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.
AB - The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.
KW - allergen immunotherapy
KW - molecular diagnosis
KW - omics
KW - personalized medicine
KW - treatable traits
UR - http://www.scopus.com/inward/record.url?scp=85092631782&partnerID=8YFLogxK
U2 - 10.1111/all.14575
DO - 10.1111/all.14575
M3 - Review Article
C2 - 32869882
AN - SCOPUS:85092631782
SN - 0105-4538
VL - 76
SP - 1041
EP - 1052
JO - Allergy
JF - Allergy
IS - 4
ER -